Commitments and Contingencies (Details Narrative) - USD ($) |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Mar. 31, 2022 |
Mar. 31, 2021 |
Dec. 31, 2021 |
|
| Description Of Study Drug And Supplemental Financial Support | The Company will provide study drug and supplemental financial support for the clinical trial | ||
| Onxeo S.A | |||
| Option And License Agreement Description | the option agreement includes clinical, regulatory, developmental and sales milestones that could reach up to $108 million if the Company achieves all milestones, and escalating royalties on net sales from 5% to 10%. | ||
| XOMA Ltd | |||
| Option And License Agreement Description | that could reach up to $14.925 million if the Company achieves all milestones | ||
| GEIS | |||
| Clinical-related Expenses | $ 300,000 | $ 0 | |
| 1000 Skokie Blvd [Member] | |||
| Operating Lease Monthly Payment | $ 4,238 | ||
| 1,202 square feet [Member] | |||
| Operating Lease Monthly Payment | 2,379 | ||
| Additional Office Space [Member] | |||
| Operating Lease Monthly Payment | $ 1,859 | ||